Le Lézard
Classified in: Health
Subjects: SVY, TDS, MAT

JUUL Labs Presents Findings From Two Studies at The Society for Research on Nicotine & Tobacco's 2018 Annual Meeting



SAN FRANCISCO, Feb. 24, 2018 /PRNewswire/ -- JUUL Labs, Inc. today announced results from a preliminary study on the temperature regulation and harmful and potentially harmful constituents (HPHCs) of JUUL's Virginia Tobacco 5% nicotine-e-liquid filled pod. The findings, "Characterization of Temperature Regulation and HPHC Profile of a Nicotine Salt-Based ENDS Product," were presented at a poster session at The Society for Research on Nicotine & Tobacco's 2018 Annual Meeting in Baltimore, Md.

Automated temperature regulation is designed to provide a consistent temperature across a range of operating conditions. In a laboratory setting, computational models of the temperature regulation performance, along with observation, were consistent with maintaining a temperature below 300 degrees Celsius under a range of operating conditions. This included a condition in which unfilled pods with a dry wick also maintained a temperature below 300 degrees Celsius.

The HPHC profile of aerosol generated from JUUL's Virginia Tobacco 5% nicotine-e-liquid filled pod was characterized at an independent contract laboratory, Enthalpy Analytical. A panel of 31 analytes and HPHCs consistent with guidance provided by the U.S. Food and Drug Administration (FDA) was measured and compared with a U.S. commercial cigarette. Beyond three intended ingredients (nicotine, propylene glycol, glycerol) which were observed, 89% (25 of 28) of panel analytes were not detected (ND) or were below the level of quantification (BQL). Eleven percent (3 of 28) were observed at quantifiable levels, including NNN (at >99% reduction vs. the combusted cigarette); chromium (at 2% above level of quantification (LOQ)), significantly below Occupational Safety and Health Administration (OSHA) permissible exposure limits; and anabasine (at 25% above LOQ), a naturally occurring nicotine degradation product. 

In addition, JUUL Labs presented data from a second poster, "Acute Use of Nicotine Salt-Based ENDS and Combusted Cigarettes," demonstrating that no significant differences in Tmax, Cmax, AUC, baseline adjusted Cmax and baseline adjusted AUC were observed between JUUL and combusted cigarettes. This was true for both ad-lib and fixed sessions. Likewise, no significant differences were observed in measures of satisfaction (p>0.05) between JUUL and combusted cigarettes. The study was a single-center, randomized, crossover design conducted by New Zealand-based Christchurch Clinical Studies Trust that included 24 adult smokers. Study participants were assigned a different product every 120 minutes, which was randomized to be either a JUUL or combusted cigarettes.

Lead authors for the studies were Dr. I. Gene Gillman of Enthalpy Analytical and Dr. Christopher Wynn of Christchurch Clinical Studies Trust.

Consistent with the FDA regulations, JUUL cannot and does not make any claims that its products are less harmful or safer than cigarettes. 

About JUUL Labs

JUUL Labs is a consumer product company dedicated to eliminating cigarettes by offering existing adult smokers a true alternative to combustible cigarettes that enables them to permanently switch. The company's research shows that hundreds of thousands of smokers have already switched to JUUL, and we are working to enable millions more to switch in the coming years through technological innovations.

Media Contact: Victoria Davis, JUUL Labs, vdavis@juul.com

SOURCE JUUL Labs, Inc.


These press releases may also interest you

9 déc 2018
Medidata was honored with the Asia Pacific Clinical Trial IT Solutions Provider of the Year Award at the annual Frost & Sullivan Asia-Pacific Best Practices Awards banquet held at Shangri-La Singapore. Aarti Chitale, senior research analyst,...

9 déc 2018
Alma Lasers, LTD, a global developer of innovative energy-based solutions for the aesthetic and surgical markets, announced today that it received a notice of completion from the US Food and Drug Administration (FDA) in response to questions about...

9 déc 2018
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences (Brii...

9 déc 2018
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the "treatment of frontotemporal dementia". The term Frontotemporal Dementia...

9 déc 2018
SECON 2019, which dedicates to develop security industry and boost global trade for all kinds of security products & solutions, will be held at Hall 3 & 4 in KINTEX, Seoul, Korea with its 22,000+m2 of exhibition area. SECON 2019, in its largest scale...

9 déc 2018
SEOUL, South Korea, Dec. 9, 2018 /PRNewswire-PRWeb/ -- CMITech Company, a leader in cost effective, high performance iris recognition systems, announced today that the Company's corporate headquarters and manufacturing facility has been moved to a...




News published on 24 february 2018 at 12:15 and distributed by: